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Chronic infections are a major factor in the development of pulmonary embolism (PE). We aimed to 
evaluate the trends of PE-related hospitalizations and PE-related deaths in people living with HIV 
(PLWH) during the era of combination antiretroviral therapy (cART) through a retrospective study 
in Spain. Data were collected from the Minimum Basic Data Set (MBDS) between 1997 and 2013. 
The study period was fragmented into four calendar periods (1997–1999, 2000–2003, 2004–2007, 
and 2008–2013). The rate of PE-related hospitalizations remained stable in PLWH (P = 0.361). HIV-
monoinfected patients had a higher incidence than HIV/HCV-coinfected patients during all follow-up 
[(98.7 (95%CI = 92.2; 105.1); P < 0.001], but PE incidence decreased in HIV-monoinfected patients 
(P < 0.001) and increased in HIV/HCV-coinfected patients (P < 0.001). Concretely, the rate of PE-related 
hospitalizations decreased significantly in patients monoinfected with HIV [from 203.6 (95%CI = 175.7; 
231.6) events per 100,000 patient-years in 1997–1999 to 74.3 (95%CI = 66.1; 82.3) in 2008–2013; 
P < 0.001], while patients coinfected with HIV/HCV had a significant increase [from 16.3 (95%CI = 11; 
21.6) in 1997–1999 to 53.3 (95%CI = 45.9; 60.6) in 2008–2013; P < 0.001]. The mortality rate of PE-
related hospitalizations showed a similar trend as PE incidence. In conclusion, the epidemiological 
trends of PE in PLWH changed during the cART era, with decreases in incidence and mortality in HIV-
monoinfected and increases in both variables in patients coinfected with HIV/HCV.
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections overlap in both modes of trans-
mission and affected populations. Around 2.3 million people living with HIV are coinfected with HCV glob-
ally, and of these, 1.3 million are injection drug users (IDUs)1. In Spain, the current prevalence of HIV-infected 
patients with HCV antibodies and active HCV infection is 37.7% and 22.1%, respectively. However, this is signif-
icantly lower than the prevalences recorded in 2002 and 20092.
HIV infection is currently a manageable chronic disease in high-income countries since the introduction of 
combination antiretroviral therapy (cART)3. Patients infected with HIV are living long enough to face significant 
morbidity from chronic illnesses such as cardiovascular disease4,5. Moreover, chronic hepatitis C has become 
significant comorbidity in HIV-infected subjects with HCV infection and seems to have a negative impact on the 
clinical course of HIV-infected patients, since it increases both HIV-associated mortality and overall mortality6,7.
Pulmonary embolism (PE) is the most clinical severe presentation of thromboembolic disease, and its 
incidence varies from country to country, with Spain having around 20–35 events per 100,000 person-year in 
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the general population8. PE causes significant morbidity and mortality and a substantial economic burden in 
developed countries9,10. The risk factors associated with PE seem to be a combination of patient-specific fac-
tors (chronic diseases, anomalies of hemostasis, age, etc.) and precipitating factors (catheterization, surgery, 
acute pathologies, acute venous stasis, chronic infections, etc.)11. Chronic infections can act as a trigger factor by 
inducing immune activation, synthesis of hepatic proteins associated with inflammation, and modification of the 
fibrinolysis and coagulation pathways11.
There is little knowledge of PE epidemiology in people living with HIV (PLWH). The incidence of venous 
thromboembolism in PLWH is higher than in non-HIV patients12,13. Malek et al. found that HIV-infected indi-
viduals are more likely to have clinically detected PE compared to non-HIV-infected individuals14. Regarding 
chronic hepatitis C, in a recent meta-analysis, HCV-infected patients showed a significantly increased risk of 
venous thromboembolism15, but no significant association was found for PE. Moreover, HIV/HCV-coinfected 
patients, when compared to HIV- or HCV-monoinfected subjects, are a subgroup that may differ regarding 
inflammatory profile and risk factor distribution16, which might influence the risk of PE differently.
We aimed to evaluate the epidemiological trends of hospitalizations related to PE and PE-related deaths in 
PLWH during the cART era in Spain.
Results
Characteristics of the study population. Overall, 267,507 patients discharged with a PE diagnosis were found 
from 1997 to 2013 in Spanish hospitals. Among those patients, 1,356 were HIV-infected subjects (899 monoinfected 
with HIV and 457 coinfected with HIV/HCV) (Table 1). HIV/HCV-coinfected subjects had higher percentages of 
tobacco abuse (P < 0.001) and chronic pulmonary disease (P < 0.001) than HIV-monoinfected subjects.
Incidence of hospitalizations related to PE. The incidences of hospitalizations related to PE (events 
per 100,000 patient-years) during the four study periods in HIV-infected patients are displayed in Fig. 1 (full 
description in Supplementary Table 1).
Overall, the incidence of hospitalizations related to PE did not show a significant variation in all HIV-infected 
patients from 1997–1999 to 2008–2013 [73.7 (95% = 64.4; 83.0) vs. 64.5 (95% = 58.9; 70.0); P = 0.532]. When we 
stratified the population by HCV status, HIV-monoinfected patients had a higher rate of PE-related hospitali-
zations than patients coinfected with HIV/HCV throughout the complete follow-up (P < 0.001). However, the 
incidence of hospitalizations related to PE had a significant decrease in HIV-monoinfected patients (P < 0.001) 
and a significant increase in patients coinfected with HIV/HCV (P < 0.001). Concretely, the incidence of hospi-
talizations related to PE decreased significantly in patients monoinfected with HIV [from 203.6 (95%CI = 175.7; 
231.6) events per 100,000 patient-years in 1997–1999 to 74.3 (95%CI = 66.1; 82.3) in 2008–2013; P < 0.001], 
while HIV/HCV-coinfected patients had a significant increase [from 16.3 (95%CI = 11; 21.6) in 1997–1999 to 
53.3 (95%CI = 45.9; 60.6) in 2008–2013; P < 0.001].
HIV-infected HIV-monoinfected HIV/HCV-coinfected p-value
No. of subjects 1356 899 457
Gender (male) 1087 (80.2%) 713 (79.3%) 374 (81.8%) 0.302
Age (years) 41 (15) 41 (17) 40 (11) 0.057
Substance abuse
Drugs 19 (1.4%) 12 (1.3%) 7 (1.5%) 0.962
Alcohol 31 (2.3%) 18 (2%) 13 (2.8%) 0.430
Tobacco 363 (26.8%) 213 (23.7%) 150 (32.8%) <0.001
Length of hospital stay (days) 15 (19) 14 (18) 15 (19) 0.978
Surgical conditions 39 (2.9%) 26 (2.9%) 13 (2.8%) 0.999
Charlson Comorbidity Index 0 (1) 1 (1) 0 (1) 0.671
Major comorbid diseases
Congestive Heart Failure 72 (5.3%) 52 (5.8%) 20 (4.4%) 0.335
Stroke 32 (2.3%) 27 (3%) 5 (1.1%) 0.045
Deep venous thrombosis 235 (17.3%) 169 (18.8%) 66 (14.4%) 0.054
Chronic Pulmonary Disease 226 (16.6%) 125 (13.9%) 101 (22.1%) <0.001
Liver Disease 169 (12.5%) 81 (9%) 88 (19.3%) <0.001
Diabetes 42 (3.1%) 35 (3.9%) 7 (1.5%) 0.027
Renal Disease 39 (2.9%) 27 (3%) 12 (2.6%) 0.825
Cancer 167 (12.3%) 101 (11.2%) 66 (14.4%) 0.107
Metastatic Carcinoma 78 (5.7%) 50 (5.6%) 28 (6.1%) 0.765
Table 1. Summary of epidemiological and clinical data of subjects with PE-related hospital admissions in 
Spain (1997 to 2013). Values were expressed as absolute number (percentage) and median (interquartile range). 
P-values were calculated by the Mann-Whitney U test and the Chi-squared test. P-values in bold indicate 
statistically significant differences between groups. Abbreviations: HIV, human immunodeficiency virus; HCV, 
hepatitis C virus; PE, pulmonary embolism.
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Mortality of PE-related hospitalizations. The mortality rate from PE-related hospitalizations (deaths 
per 100,000 patient-years) during the four study periods in HIV-infected patients are displayed on Fig. 2 (full 
description in Supplementary Table 2). The mortality rate remained stable in all HIV-infected patients (P = 0.199) 
and did not show significant differences between 1997–1999 and 2008–2013 [14.1 (95%CI = 10.0; 18.1) vs. 10.2 
(95%CI = 8.0; 12.4); P = 0.517]. When we stratified the population by HCV status, HIV-monoinfected patients 
had a higher rate of mortality in PE-related hospitalizations than patients coinfected with HIV/HCV in the early 
calendar period (1997–1999) [41.9 (95%CI = 29.2; 54.6) vs. 1.8 (95%CI = 0; 3.5); P < 0.001]. Next, the mortality 
of PE-related hospitalizations fell sharply in patients monoinfected with HIV [from 41.9 (95%CI = 29.2; 54.6) 
in 1997–1999 to 17.4 (95%CI = 11; 23.9) in (2000–2003; P = 0.002], and maintained a plane during the late cal-
endar periods [12.6 (95%CI = 7.8; 17.3) in 2004–2007 and 11.5 (95%CI = 8.3; 14.7) in 2008–2013]. On the con-
trary, the mortality rate of PE-related hospitalizations increased in patients coinfected with HIV/HCV [from 
1.8 (95%CI = 0; 3.5) in 1997–1999 to 8.7 (95%CI = 5.8; 11.7) in 2008–2013; P = 0.002]. In the calendar period 
2008–2013, patients monoinfected with HIV and patients coinfected with HIV/HCV had similar mortality rates 
(P = 0.225).
The CFR rates for PE hospitalizations related to PE are displayed in Supplementary Table 3. The trend of 
the CFR rate did not change during the follow-up (1997–2013) in the study groups (All HIV-infected patients, 
monoinfected with HIV, and coinfected with HIV/HCV). Furthermore, these three study groups showed similar 
CFR values. Finally, HCV coinfection was not associated with a higher odds of death when we performed an 
adjusted logistic regression (Fig. 3).
Figure 1. Incidence of pulmonary embolism in Spain among patients infected with HIV (1997–2013) stratified 
by HCV status. P-values: (*), differences calculated by the exact confidence intervals for incidence (patients 
monoinfected with HIV versus patients coinfected with HIV/HCV). The linear trends were estimated by the 
Extended Mantel Haenszel Chi-Square: (§) patients monoinfected with HIV (1997–1999 to 2008–2013); (†), all 
patients infected with HIV (1997–1999 to 2008–2013); (‡), patients coinfected with HIV/HCV (1997–1999 to 
2008–2013). At the base of the panels, we show the total number of hospitalization in each calendar period and 
study group. Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus.
Figure 2. In-hospital mortality in Spain (1997–2013) among in patients infected with HIV with pulmonary 
embolism stratified by HCV status. P-values: (*), differences calculated by the exact confidence intervals for 
incidence (patients monoinfected with HIV versus patients coinfected with HIV/HCV). The linear trends were 
estimated by the Extended Mantel Haenszel Chi-Square: (§) patients monoinfected with HIV (1997–1999 to 
2008–2013); (†), all patients infected with HIV (1997–1999 to 2008–2013); (‡), patients coinfected with HIV/
HCV (1997–1999 to 2008–2013). At the base of the panels, we show the total number of hospitalization in each 
calendar period and study group. Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus.
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Discussion
In this study, trends in both incidence and mortality of PE-related hospitalizations did not show a significant 
variation in all PLWH (patients monoinfected with HIV plus patients coinfected with HIV/HCV) during the 
entire follow-up (1997–2013). However, we found significant differences when PLWH were stratified by HCV 
status. Thus, both incidence and mortality of PE-related hospitalizations decreased in patients monoinfected 
with HIV during the follow-up, whereas both rates increased in HIV/HCV-coinfected subjects. However, patients 
monoinfected with HIV had a higher incidence of PE in the last cART period (2008–2013) than in patients coin-
fected with HIV/HCV, whereas the mortality from PE-related hospitalizations was similar in both groups. To 
our knowledge, our study is the first report evaluating epidemiological trends of PE-related hospitalizations in 
patients monoinfected with HIV stratified by their HCV serostatus.
The prothrombotic state in PLWH seems to be multifactorial17,18. Altered parameters related to inflamma-
tion (for example, IL-6, TNF-RI, and C-reactive protein) and coagulation (for example, tissue factor expression, 
FVIII, thrombin, fibrinogen, protein C, protein S, and D-dimer levels) have been found in these patients both 
without antiretroviral therapy and while on cART17,19,20. However, cART may improve the hypercoagulable state, 
but does not normalize most parameters21. Moreover, HCV coinfection and severity of liver disease are related 
to an increased prothrombotic state, since elevated levels of inflammation and coagulation have been described 
in HIV/HCV-coinfected patients22–24. Although there are fewer data in patients coinfected with HIV/HCV, there 
also appears to be a reduction in the prothrombotic state after achieving sustained virological response with HCV 
antiviral therapy25,26.
Our study shows that the epidemiological trends of PE in PLWH were different from the data of the general 
population in Spain8. In a recent article made with data from the Spanish MBDS, Miguel-Dıez et al.8 found 
that the PE incidence increased from 20.4 to 32.7 hospitalizations per 100,000 person-years in Spain and the 
mean in-hospital mortality decreased from 12.9% in 2002 to 8.32% in 2011. Another remarkable finding in our 
study was that the incidence, mortality, and CFR in PLWH (patients monoinfected with HIV plus patients coin-
fected with HIV/HCV) did not change during the follow-up. However, the incidence of hospitalizations related 
to PE was higher than in HIV seronegative patients in Spain, whereas CFR values were only slightly higher in 
HIV-infected patients8.
In our study, HIV-monoinfected patients showed a significant decrease both in incidence and mortality for 
PE-related hospitalizations. The increasing use of cART may have influenced these findings. The percentage of 
PLWH on cART increased significantly in Spain during the last decade27, increasing the percentage of patients 
with undetectable HIV viral load and higher CD4+ T-cell counts27, and decreasing their risk of cardiovascular 
events28. Furthermore, the enhancement in preventive interventions to reduce the cardiovascular risk in PLWH 
on cART has decreased the mortality related to cardiovascular disease in high-income countries3.
In this study, patients coinfected with HIV/HCV had a reverse temporal trend of both incidence and mortality 
for PE-related hospitalizations compared to patients monoinfected with HIV. In the calendar period 1997–1999, 
the values of incidence and mortality of hospitalizations related to PE was far lower in patients coinfected with 
HIV/HCV than in patients monoinfected with HIV; but both rates increased significantly in patients coinfected 
with HIV/HCV in the following years. In the last calendar period (2008–2013), the PE incidence related to hos-
pitalizations was lower in patients coinfected with HIV/HCV than in patients monoinfected with HIV, but the 
mortality of PE-related hospitalizations was similar for both groups. The explanation for these epidemiological 
trends is not simple, especially if we consider that our data source was the MBDS. On the one hand, over the study 
period, HCV screening might have been different in patients admitted to hospitals with a PE diagnosis (e.g., 
more HCV testing in the later periods than during earlier periods in HIV-positive patients), but HCV screening 
in PLWH has not changed significantly in Spain over the study period (around 95%)2,29. On the other hand, the 
death could have been an important competing risk for PE in patients coinfected with HIV/HCV during all 
follow-up, since the mortality trend for HIV-infected subjects declined significantly in Spain, primarily at the 
expense of patients monoinfected with HIV, while mortality among patients coinfected with HIV/HCV did not 
decline30. Additionally, the primary mode of HIV acquisition in patients infected with HCV was the injection 
drug use2,27,29, and these subjects had a high risk of death2. In fact, intravenous drug use in HIV-infected patients 
is a significant factor for right-sided endocarditis and PE31. However, we did not have data on active or recent 
intravenous drug use to evaluate its influence on PE trends and the real impact of chronic hepatitis C. Also note 
that more efficacious and safer cART regimens32 and an increasing treatment uptake of anti-HCV therapy2 in 
patients coinfected with HIV/HCV have been associated with mortality reduction in these patients6,33–35.
Figure 3. Adjusted likelihoods of death among patients infected with HIV with pulmonary embolism in Spain 
(1997–2013) stratified by HCV status. Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency 
virus, aOR, adjusted odds ratio; 95%CI, 95% of confidence interval.
www.nature.com/scientificreports/
5SCIENtIFIC REPORTS |  (2018) 8:12137  | DOI:10.1038/s41598-018-29739-2
Limitations
Finally, several aspects must be considered for the correct interpretation of the results.
Firstly, we did not have figures for the global number of PLWH in Spain from 1997 to 2013, since there was 
no data of national coverage of HIV diagnoses in our country during this period. Instead, we used PLWH esti-
mation data from the National Centre of Epidemiology (NCE, Instituto de Salud Carlos III, Madrid, Spain)36. 
However, NCE did not provide data of gender, age or comorbidities and we could not calculate the rates stratified 
by the main cardiovascular risk factors (gender, age, diabetes, hypertension, etc.). Secondly, it was not known 
how many patients with thrombosis did not need any hospital admission for systemic anticoagulation or how 
many patients died before hospital admission, since the MBDS only provides information about hospitalized 
patients. Additionally, the hospitalization may be avoided in many patients with thrombosis due to the develop-
ment of better drugs for outpatient treatment37. This fact may be more likely to occur for patients monoinfected 
with HIV than patients coinfected with HIV/HCV because coinfection with HCV leads to more frequent liver 
disease that requires hospitalization. Thirdly, we did not have access to critical clinical and epidemiological data 
related to HIV infection and PE management, which could have helped us to interpret our results more thor-
oughly. Fourthly, the presence of anti-HCV antibodies defined the HCV status because we did not have any data 
about active HCV infection (HCV-RNA in serum or plasma), which creates an overestimation of the number 
of HCV-infected patients. Finally, we could not assess the impact of HCV therapy on the PE trends in patients 
coinfected with HIV/HCV.
Conclusions
In conclusion, the epidemiological trends of PE in PLWH changed during the cART era, with decreasing values 
of both incidence and mortality in patients monoinfected with HIV and increases of both rates in patients coin-
fected with HIV/HCV. Further studies are needed to investigate the impact of lifestyle, active HCV infection, and 
HCV clearance following HCV therapy.
Materials and Methods
Study population. We performed a retrospective study of all subjects older than 16 years who were dis-
charged with a PE diagnosis from Spanish hospitals from January 1, 1997, to December 31, 2013. The study period 
was divided into four calendar periods38: (a) 1997–1999; (b) 2000–2003; (c) 2004–2007; and (d) 2008–2013.
Data of patients were collected from the Minimum Basic Data Set (MBDS) of the Ministry of Health, 
Consumption and Social Welfare (MHCSW). Data were collected in 2016 and analyzed in 2017. The MBDS 
contains clinical and epidemiological data recorded at the hospital discharge. The MDBS has 92% coverage of all 
Spanish hospitals [public hospitals (84.14%) and private hospitals (15.86%)]39. Additionally, 100% of the Spanish 
population has free medical care provided by the National Health System (MHCSW).
The MBDS included 14 discharge diagnoses and 20 procedures performed during the hospital stay according 
to the International Classification of Diseases, 9th ed, Clinical Modification (ICD-9-CM). Furthermore, the MBDS 
provided the date of birth, sex, dates of hospital admission and discharge, and outcome at discharge. The Spanish 
MHCSW has established standards for record keeping and conducts periodic audits.
Ethics statement. The MHCSW requested hospitals the health-related personal data, which were added to 
Spanish MBDS according to Spanish legislation40. The MHCSW approved our study and the data were treated 
with full confidentiality and. The signed patient’s consent was not needed since MBDS is an anonymous dataset 
and has a mandatory nature. Moreover, the Research Ethics Committee (Comité de Ética de la Investigación y 
de Bienestar Animal; CEI PI 69_2012) of the Instituto de Salud Carlos III (Madrid, Spain) approved our study.
Study groups. Viral infection status was defined by ICD-9-CM codes (see Supplementary Table 4): (i) HIV 
infection (042 or V08); (ii) HCV infection (070.41, 070.44, 070.51, 070.54, 070.7x, or V02.62); (iii) HBV infection 
(070.2x, 070.3x, or V02.61). Patients with HBV infection were excluded. From these ICD-9-CM codes, three 
groups were established: (i) HIV-infected (all patients infected with HIV); (ii) HIV-monoinfected (only HIV); 
(iii) HIV/HCV-coinfected (both HIV and HCV). We did not have any information about if a person had the diag-
nosis of HIV infection and HCV infection previously, concomitantly to, or after the diagnosis of PE.
Outcome variables. We selected subjects with PE diagnosis codes [415.11 and 415.19 (see Supplementary 
Table 4)] in the MBDS, according to the criteria of Miguel-Diez et al.8. The PE diagnosis was performed according 
to the standard radiological procedure in each hospital of the Spanish National Health System by using computed 
tomography pulmonary angiography, pulmonary scintigraphy, or others. The diagnostic code for PE was assigned 
by physicians when the diagnostic imaging was positive (see examples in Supplementary Figure 1). A discharge 
record with a PE diagnosis in the MBDS was defined a PE-related hospitalization. The first hospital discharge 
with PE diagnosis was defined as the index episode. Patients readmitted with a later PE event (included in any 
position) were not identified as new episodes of PE. We analyzed the following outcome variables: i) new PE 
diagnosis (incidence); ii) death among patients with PE diagnosis (in-hospital PE mortality). We did not have 
any information about if a person died in the days or few weeks following discharge, which could have also been 
attributed to PE.
Reference populations. The NCE provided the estimation of the number of PLWH in Spain (see 
Supplementary Table 5)38. We also estimated the number of people monoinfected with HIV and HIV/
HCV-coinfected in Spain using data from the hospital survey of HIV/AIDS patients coordinated by the NCE27, 
and the reports of the “Grupo de Estudio de Sida” (GeSIDA)41 and the “Asociación Médica VACH de Estudios 
Multicéntricos (AMVACH)”42.
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Statistical analysis. We calculated the PE incidence (new PE cases per 100,000 patient-years) and PE mor-
tality (in-hospital PE-related deaths per 100,000 patient-years) as the ratio between the number of events and 
the number of persons at risk within each calendar period, according to reference populations (see the previous 
section). The case fatality rate (CFR) was the ratio between the number of patients with PE-related deaths and the 
number of patients with a PE-related hospitalization (percentage, %).
The chi-squared test and Fisher’s exact test were used to analyze categorical data and proportions, as was 
required. Continuous variables were studied using the T-Test or Mann-Whitney U test. The Extended Mantel 
Haenszel Chi-Square was used for evaluating the temporal trends of rates. Multivariate logistic regressions were 
used to calculate the odds for in-hospital PE-related death adjusted by age, sex, tobacco usage, and Charlson 
co-morbidity index (CCI).
The R statistical package version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria) was used 
to perform the statistical analysis. All the statistical tests were considered significant with values of p < 0.05 
(two-tailed).
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